Could GLP1RA drugs lower high iron levels?
Increased iron levels can be dangerous for those with type 2 diabetes.
GLP1RA could drugs lower high iron levels, study finds
GLP1RA agonists have been increasing in popularity for treating obesity and type 2 diabetes.
Ozempic, Wegovy maker grilled by Bernie Sanders-led committee over high prices
The Senate Health, Education, Labor and Pension committee, led by Vermont Sen. Bernie Sanders, is hearing testimony from Novo Nordisk CEO Lars Fruergaard Jørgensen on the exhortative prices for their drugs in the U.S. CBS News’ Nancy Chen has more.
Novo Nordisk’s CEO took the Washington hot seat over Ozempic prices. 3 takeaways from his testimony
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.Read more…
Ozempic and Wegovy drugmaker CEO defends high costs of drugs
Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the company’s weight-loss drugs Ozempic and Wegovy. NBC News’ Christine Romans reports on how Jørgensen claimed the high prices were due to complications of the U.S. healthcare system.
Radiotherapy Increases Sarcoma Risk in TP53 Breast Cancer
A retrospective analysis found an 8.8% cumulative risk for sarcoma following radiation therapy in carriers of TP53 pathogenic variant at 15 years. Medscape Medical News
STAT+: Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices
The hearing is the latest move in Sanders’ crusade to pressure drugmakers to lower their prices.
Blame drug ‘middlemen’ for Ozempic and Wegovy prices, Novo Nordisk CEO tells Congress
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.Read more…
Ozempic maker to testify before Senate committee on weight loss drug prices
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on Tuesday.
STAT+: Metsera’s GLP-1 drug has potential for monthly dosing, new data show
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy. Here’s what to expect.